Phase 2 Study: L-SABR Plus Standard Therapy in Metastatic NSCLC Patients
This Phase 2 trial evaluates the addition of liver stereotactic ablative radiotherapy (L-SABR) to standard drug therapy in metastatic NSCLC. The primary endpoint is median progression-free survival, w…
Researchers are studying if adding a special type of radiation therapy helps patients with advanced lung cancer live longer without their disease getting worse. They are comparing this approach to sta…
Ivonescimab Phase II Study Targets 55% DCR in Relapsed Pleural Mesothelioma
A Phase II trial evaluates ivonescimab in 38 pleural mesothelioma patients post-immunotherapy/chemotherapy. The study aims for a ≥55% disease control rate at 12 weeks.
Researchers are testing a new drug called ivonescimab for patients whose pleural mesothelioma has come back after other treatments. The study aims to see if this drug can help control the disease bett…